Health CanadaGeneral Alert
Important Safety Information on anti-TNFα Therapy: ENBREL (etanercept), HUMIRA (...
Published: January 18, 2006Recall ID: 24174Category: generalCountry: Canada
Product Description & Identification
Important Safety Information on anti-TNFα Therapy: ENBREL (etanercept), HUMIRA (adalimumab), and REMICADE (infliximab) - For Health Professionals
Additional Source Details
| Field | Value |
|---|---|
| N I D | 24174 |
| U R L | https://recalls-rappels.canada.ca/en/alert-recall/important-safety-information-anti-tnfa-therapy-enbrel-etanercept-humira-adalimumab-and |
| Title | Important Safety Information on anti-TNFα Therapy: ENBREL (etanercept), HUMIRA (adalimumab), and REMICADE (infliximab) - For Health Professionals |
| Archived | 1 |
| Category | Biologic or vaccine |
| Last updated | 2006-01-18 |
| Organization | Marketed health products |